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A B S T R A C T
The 4th edition of the European Code against Cancer recommends limiting – or avoiding when possible –
the use of hormone replacement therapy (HRT) because of the increased risk of cancer, nevertheless
acknowledging that prescription of HRT may be indicated under certain medical conditions. Current
evidence shows that HRT, generally prescribed as menopausal hormone therapy, is associated with an
increased risk of cancers of the breast, endometrium, and ovary, with the risk pattern depending on
factors such as the type of therapy (oestrogen-only or combined oestrogen–progestogen), duration of
treatment, and initiation according to the time of menopause. Carcinogenicity has also been established
for anti-neoplastic agents used in cancer therapy, immunosuppressants, oestrogen–progestogen
contraceptives, and tamoxifen. Medical use of ionising radiation, an established carcinogen, can provide
major health beneﬁts; however, prudent practices need to be in place, with procedures and techniques
providing the needed diagnostic information or therapeutic gain with the lowest possible radiation
exposure. For pharmaceutical drugs and medical radiation exposure with convincing evidence on their
carcinogenicity, health beneﬁts have to be balanced against the risks; potential increases in long-term
cancer risk should be considered in the context of the often substantial and immediate health beneﬁts
from diagnosis and/or treatment. Thus, apart from HRT, no general recommendations on reducing cancer
risk were given for carcinogenic drugs and medical radiation in the 4th edition of European Code against
Cancer. It is crucial that the application of these measures relies on medical expertise and thorough
beneﬁt–risk evaluation. This also pertains to cancer-preventive drugs, and self-medication with aspirin
or other potential chemopreventive drugs is strongly discouraged because of the possibility of serious,
potentially lethal, adverse events.
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1.1. Introduction
The 4th revision of the European Code against Cancer (Box 1)
aims to give recommendations to reduce the risk of cancer through
personal behavioural changes or participation in organised
intervention programmes [1]. In this context, medical exposures
differ from recommendations regarding, for example, smoking,
sun exposure, or dietary habits, since most medical exposures are
not controlled by the individual but administered as diagnostic or
therapeutic measures by healthcare professionals. Therefore,for Research on Cancer; Licensee ELSEVIER Ltd
Box 1. European Code Against Cancer
EUROPEAN CODE AGAINST CANCER
12 ways to reduce your cancer risk
1 Do not smoke. Do not use any form of tobacco.
2 Make your home smoke free. Support smoke-free policies
in your workplace.
3 Take action to be a healthy body weight.
4 Be physically active in everyday life. Limit the time you
spend sitting.
5 Have a healthy diet:
 Eat plenty of whole grains, pulses, vegetables and fruits.
 Limit high-calorie foods (foods high in sugar or fat) and
avoid sugary drinks.
 Avoid processed meat; limit red meat and foods high in
salt.
6 If you drink alcohol of any type, limit your intake. Not
drinking alcohol is better for cancer prevention.
7 Avoid too much sun, especially for children. Use sun
protection. Do not use sunbeds.
8 In the workplace, protect yourself against cancer-causing
substances by following health and safety instructions.
9 Find out if you are exposed to radiation from naturally high
radon levels in your home. Take action to reduce high
radon levels.
10 For women:
 Breastfeeding reduces the mother’s cancer risk. If you
can, breastfeed your baby.
 Hormone replacement therapy (HRT) increases the risk
of certain cancers. Limit use of HRT.
11 Ensure your children take part in vaccination pro-
grammes for:
 Hepatitis B (for newborns).
 Human papillomavirus (HPV) (for girls).
12 Take part in organized cancer screening programmes for:
 Bowel cancer (men and women).
 Breast cancer (women).
 Cervical cancer (women).
The European Code against Cancer focuses on actions that
individual citizens can take to help prevent cancer. Success-
ful cancer prevention requires these individual actions to be
supported by governmental policies and actions.
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Cancer is the general public, guidance on medical exposures should
also be directed toward healthcare professionals. A new challenge
is the increasing accessibility of drugs through web-based
providers, typically without oversight by healthcare professionals
or proper instructions for use.
Medical exposures encompass pharmaceutical drugs and the
use of ionising radiation in medical diagnostics or therapy. In use of
pharmaceutical drugs or ionising radiation, potential increases in
the long-term risk of cancer or other adverse effects need to be
considered in the context of health beneﬁts – often substantial and
immediate – from diagnosis and/or treatment. Chemotherapy and
radiotherapy represent classical examples of the need for such
careful beneﬁt/risk evaluations, since both types of therapy may
induce development of second malignancies, besides their ability
to improve survival from the primary cancer being treated. For
measures of screening and prevention, the beneﬁt/risk ratio is
generally lower than for therapeutic measures: e.g. in the use ofX-rays in routine health checks or in the use of tamoxifen for breast
cancer prevention. For all new medical interventions, the beneﬁts
should be demonstrated by rigorous research, ideally by random-
ised trials.
The primary objective of the present review was to provide the
scientiﬁc justiﬁcation for the recommendation on hormone
replacement therapy (HRT), today predominantly prescribed as
menopausal hormone therapy (and evaluated as such in the
review), for which the Code recommends: “Hormone replacement
therapy (HRT) increases the risk of certain cancers. Limit use of
HRT”. This recommendation is based on unequivocal scientiﬁc
evidence that HRT is carcinogenic to humans and may induce
cancers in female genital organs and breast [2,3]. Although
treatment with HRT remains justiﬁed under certain medical
conditions, the general population should be informed about the
cancer risk and avoiding use of HRT outside deﬁned indications.
Carcinogenicity has also been established for several other medical
exposures, including medications other than HRT and medical use
of ionising radiation; however, no general recommendations were
given for these measures in the 4th edition of the European Code
against Cancer as their use relies on medical expertise and
thorough beneﬁt–risk evaluation in each individual.
1.2. Pharmaceutical drugs
A number of drugs used in medical practice have been
established as carcinogenic to humans [3]. Some of these drugs
– e.g. anti-neoplastic agents – exhibit a high beneﬁt–risk ratio
under the approved indications, and continued use of these drugs
is endorsed [4]. In contrast, a decision to prescribe and use any
drug with established or probable carcinogenicity (e.g. HRT) for
non-life-threatening conditions is more problematic [5,6]. Irre-
spective of drug type and indication, it is imperative to monitor
potential long-term carcinogenicity of drugs, because of the
limited evidence of carcinogenic potential at the time of licensing.
At that time, knowledge of the carcinogenic potential is based
almost exclusively on preclinical studies, since the pre-marketing
randomised clinical trials with limited sample sizes and follow-up
are not well suited to the study of rare outcomes such as cancer,
which typically has a long latency period [7–9]. Several drugs have
been evaluated for potential cancer-preventive properties: i.e.
their ability to interrupt mechanisms or pathways that initiate or
accelerate development of cancer [10,11]. Currently, only a few
drugs have been approved for cancer preventive therapy: e.g.
tamoxifen for women at high risk of breast cancer. However,
several drugs are under evaluation as preventive or adjuvant
therapies against cancer, including for example aromatase
inhibitors, aspirin, metformin, and statins [9].
1.3. Medical exposure to ionising radiation
Since the discovery of x-rays and radioactivity, radiation has
been extensively utilised in medicine. Radiation has an important
role in both diagnosis and treatment of a wide range of diseases,
including cancer. The major medical applications of radiation
include radiology, radiotherapy and nuclear medicine. Develop-
ments in medical imaging – particularly in computed tomography
(CT) and its combinations with other imaging techniques – have
led to substantial increases in relatively high-dose X-ray exami-
nations. Medical radiation has become the second most important
source of exposure to radiation for an average European citizen,
after exposure to radon in homes [12]. To alert health professionals
about potentially higher doses received by patients from some of
the diagnostic procedures, the European Union Euratom directive
97/43 categorised CT and interventional radiology as procedures
that expose patients to high doses of radiation. For illustration, a
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radiographs (chest tomography 8 mSv; chest radiography 0.02
mSv) [13].
2. Cancer association with medical exposures
2.1. Carcinogenicity of hormonal therapy and other pharmaceutical
drugs
Starting in the 1970s, the International Agency for Research on
Cancer (IARC) has evaluated a wide range of drug exposures to
assess their carcinogenic effects in humans, based on comprehen-
sive literature reviews by expert committees [14]. In a recent
volume (100A) of the Monographs Programme, the IARC reaf-
ﬁrmed the categorisation as carcinogenic to humans (Group 1) for
20 pharmaceutical agents and upgraded three agents from Group
2A (probably carcinogenic to humans) to Group 1 [3]. The latter
included phenacetin per se, which was previously classiﬁed as a
Group 1 agent only as part of “analgesic mixtures containing
phenacetin”. The majority of the Group 1 agents derive from two
therapeutic categories: hormonal therapy and anti-neoplastic
therapy (Tables 1 and 2).
2.1.1. Menopausal hormone therapy
HRT includes various forms, doses, and regimens of oestrogen,
either alone or combined with progestogen [15]. Oestrogen-only
therapy was introduced in the 1960s, and its use increased until the
mid-1970s, when evidence indicated a strong association between
HRT and endometrial cancer [16,17]. Then, among non-hysterec-
tomised women, the oestrogen-only regimen was replaced by
combined oestrogen–progestogen therapy [18], which was used
increasingly through the 1980s and 1990s [16,17]. Despite concern
about the potential for increased risk of breast cancer [19], it was
generally believed that HRT was associated with a net health
beneﬁt, which included prevention of cardiovascular disease [20].
However, this view changed dramatically in 2002, when the ﬁrst
results from the Women's Health Initiative (WHI) clinical trial
[21,22] contrasted with ﬁndings from many observational studies
[23]. Among 16,608 women aged 50–70 years at baseline, use of
combined oestrogen–progestogen treatment was associated with
a risk ratio (RR) for coronary heart disease of 1.24 (95% conﬁdence
interval [CI]: 1.00–1.54) compared to placebo, after a mean follow-
up of 5.2 years [21,22]. A similar WHI trial included 10,739 women,
aged 50–79 years and with prior hysterectomy, who were
randomised to oestrogen-only therapy or placebo [24]. BothTable 1
Hormonal treatments assessed by the IARC Monographs Programme.
Carcinogenic agent Cancer sites with sufﬁcient evidence of carcinogenicity in
humans
Ca
w
re
Combined oestrogen–
progestogen
menopausal therapy
Endometrium (risk decreases with number of days per
month of progestogen use); breast
– 
Oestrogen-only
menopausal therapy
Endometrium, ovary
(Limited evidence: breast)
– 
Combined oestrogen–
progestogen oral
contraceptives
Breast, cervix, liver (hepatocellular carcinoma) En
ov
Diethylstilbestrol Breast (exposure during pregnancy), vagina and cervix
(clear-cell adenocarcinoma; exposure in utero)
[Limited evidence; endometrium (exposure during
pregnancy), cervix (squamous carcinoma; exposure in
utero), testis (exposure in utero)]
– 
Tamoxifen Endometrium BrWHI trials were halted prematurely, because interim analyses
indicated that the risks of both oestrogen regimens outweighed
their beneﬁts [21,24].
The WHI study was followed by reports of sharp declines in
breast cancer incidence in both the United States and Europe
[25–27]. This trend has been interpreted to be a direct result of
modiﬁed recommendations for menopausal hormone therapy
[28–30], although this has been met with some scepticism [31].
Recently, healthcare agencies in the United States and Europe
have concluded that HRT is not suitable for primary prevention of
chronic diseases [32–35]. Although there is some evidence that use
of HRT protects against cardiovascular disease if started early in
menopause [36,37], a recent Cochrane review of 19 cardiovascular
trials concluded that use of HRT in postmenopausal women overall
“has little if any beneﬁt” in either primary or secondary prevention
of cardiovascular disease, and causes an increase in the risk of
stroke and venous thromboembolic events [38]. Thus, HRT should
primarily be used for the short-term treatment of menopausal
symptoms [32–35]. There is no consensus, however, on the
deﬁnition of “short-term”, and there are unresolved questions
about the inﬂuence of menopausal hormone therapies on risks of
speciﬁc cancer types.
2.1.1.1. Breast cancer. Based on a large body of evidence, the IARC
has concluded that long-term use of combined oestrogen–
progestogen HRT is associated with an increased risk of breast
cancer (Table 1) [3]. The initial WHI study reported an RR of 1.26
(CI: 1.00–1.59) for breast cancer associated with the use of
oestrogen–progestogen therapy [21], but patients in the
oestrogen-only arm of the WHI study experienced a reduced
risk of breast cancer (RR 0.77; CI: 0.59–1.01) [24]. Numerous
observational studies have reported that HRT is associated with an
increased risk of breast cancer, and generally associations have
been stronger and more consistent for combined oestrogen–
progestogen menopausal therapy than for oestrogen-only therapy
[19,39–44]. In the Million Women Study in the United Kingdom
(UK) [39,43], women were younger (average age 55.9 years) at
cohort entry (1996–2001) than participants in the WHI study
(average age 64 years) [21], enabling a more comprehensive
evaluation of the impact of timing on HRT [43]. While the results of
the two studies were similar for oestrogen–progestogen therapy,
the Million Women Study found an increased risk of breast cancer
with oestrogen-only therapy [39,43], in contrast to the inverse
association observed in the WHI Study [24]. Additional analyses of
the two studies have indicated that the risk differences observedncer sites
here risk is
duced
Established mechanisms Other likely mechanisms
Receptor-mediated events Oestrogen genotoxicity
Oestrogen receptor-
mediated events
Genotoxicity
dometrium,
ary
Receptor-mediated events Oestrogen genotoxicity; hormone-
stimulated expression of human
papilloma virus genes
Oestrogen-receptor-
mediated events (vagina,
cervix), genotoxicity
Epigenetic programming
east Oestrogen-receptor-
mediated events,
genotoxicity
–
Table 2
Anti-neoplastic drugs and other drugs evaluated by the IARC Monographs Programme.
Group 1 agent Cancer sites with sufﬁcient evidence of
carcinogenicity in humans
Established mechanisms
Anti-neoplastic agents
Busulfan Acute myeloid leukaemia Genotoxicity (alkylating agent)
Chlorambucil Acute myeloid leukaemia Genotoxicity (alkylating agent)
Chlornaphazine Urinary bladder Genotoxicity (alkylating agent, metabolism to 2-naphthylamine derivatives)
Cyclophosphamide Acute myeloid leukaemia, urinary
bladder
Genotoxicity (metabolism to alkylating agents)
Etoposide (Group 2A in 2000) [Limited evidence: acute myeloid
leukaemia]
Genotoxicity, translocations involving MLL gene
Etoposide in combination with
cisplatin and bleomycin
Acute myeloid leukaemia Genotoxicity, translocations involving MLL gene (etoposide)
Melphalan Acute myeloid leukaemia Genotoxicity (alkylating agent)
MOPPa combined chemotherapy Acute myeloid leukaemia, lung Genotoxicity
Semustine (methyl-CCNU) Acute myeloid leukaemia Genotoxicity (alkylating agent)
Thiotepa Leukaemia Genotoxicity (alkylating agent)
Treosulfan Acute myeloid leukaemia Genotoxicity (alkylating agent)
Immunosuppressive agents
Azathioprine Non-Hodgkin lymphoma, skin Genotoxicity, immunosuppression
Cyclosporin Non-Hodgkin lymphoma, skin, multiple
other sites
Immunosuppression
Other carcinogenic agents
Analgesic mixtures containing
phenacetin
Renal pelvis, ureter (See phenacetin in text)
Aristolochic acid (Group 2A in
2002)
– Genotoxicity, DNA adducts in animals are the same as those found in humans exposed to
plants, A:T ! T:A transversions in TP53; RAS activation
Methoxsalen plus ultraviolet A
radiation
Skin Genotoxicity following photo-activation
Phenacetin (Group 2A in 1987) Renal pelvis, ureter Genotoxicity, cell proliferation
Plants containing aristolochic acid Renal pelvis, ureter Genotoxicity, DNA adducts in humans, A:T ! T:A transversions in TP53 in human tumours
a Chlormethine (mechlorethamine), vincristine (oncovin), procarbazine, and prednisone.
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distribution and anthropometric measures [43,45–47]. In a recent
update of the Million Women Study, the use of oestrogen-only
agents was associated with a 43% increase in the risk of breast
cancer (RR 1.43; CI: 1.35–1.51) when treatment had begun less than
5 years after menopause; however, when oestrogen-only therapy
was initiated 5 years or more after menopause, there was no
inﬂuence on breast cancer risk (RR 1.05; CI: 0.89–1.24) [43]. A
similar tendency was observed in the WHI study; breast cancer risk
was reduced among women who ﬁrst started oestrogen-only
therapy 5 years or more after menopause (HR 0.65; CI: 0.48–0.89),
whereas the association was close to unity among women who
initiated treatment closer to menopause (HR 0.89; CI: 0.66–1.20)
[48]. Thus, oestrogen-only therapy may be associated with a
neutral or increased risk of breast cancer when started close to the
time of menopause, but when started later in menopause it may be
associated with a neutral or even reduced breast cancer risk
[43,47–49]. In addition, in both the Million Women Study and the
WHI study, breast cancer risk associated with oestrogen-only
therapy was higher among women with a low body mass index
than among overweight or obese women [50,51]. Since women in
the WHI study had on average higher body mass index than
women in the Million Women Study, this contributes to an
explanation of the difference in overall ﬁndings for oestrogen-only
therapy and breast cancer risk in these two landmark studies [47].
The relationship between HRT and breast cancer risk is thus
complex and varies with age at menopause, age at initiation of
hormone therapy, anthropometric measures, and other breast
cancer risk factors [47,52–55]. Moreover, there is no clear
consensus about when to discontinue HRT, if started at normal
menopause [32–35]. Notwithstanding the uncertainties, the
current evidence indicates that breast cancer risk associated with
the use of HRT is higher when treatment is started close tomenopause [43,47,51,56]; it occurs after a few years of treatment
[21,28,39,43,57]; it increases with treatment duration [43,58–61];
and it declines within a few years after treatment cessation [58,62].
2.1.1.2. Endometrial cancer. Oestrogen-only menopausal therapy is
known to induce endometrial hyperplasia and cancer (Table 1)
[63]. The excess risk depends on the dose of oestrogen and
treatment duration; reports vary between two-fold and ten-fold
risk elevations [64,65]. Current evidence indicates that continuous
combined oestrogen–progestogen regimens may be associated
with a neutral or even reduced risk of endometrial cancer, whereas
sequential regimens may impose an increased risk when the
progestogen component is prescribed for less than 10–15 days per
month [66–69]. A recent meta-analysis of observational studies
reported a risk reduction of endometrial cancer with continuous
(>25 days per month) oestrogen–progestogen therapy (pooled RR
0.78; CI: 0.72–0.86) [69]. The corresponding RR for sequential
oestrogen–progestogen therapy with less than 10 days
progestogen per month was 1.76 (CI: 1.51–2.05); in contrast,
there was no association with regimens with 10–24 days of
simultaneous oestrogen–progestin administration (RR 1.07; CI:
0.92–1.24) [69]. It is unclear whether the suggested reduced risk of
endometrial cancer associated with continuous oestrogen–
progestogen regimens persists with long-term use. Unresolved
issues also include the inﬂuence of oestrogen or progestogen
dosages, mode of administration, and potential risk variations for
different types of endometrial cancer [69].
2.1.1.3. Ovarian cancer. In the 100A volume of the Monographs
Programme, the IARC concluded that oestrogen-only hormone
therapy is causally associated with an increased risk of ovarian
cancer (Table 1), whereas data to support any ﬁrm conclusions on
combined oestrogen–progestogen agents were regarded as
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increased pooled RRs for ovarian cancer for each 5 years of
oestrogen-only or oestrogen–progestogen treatment (1.22, CI:
1.18–1.27; and 1.10, CI: 1.04–1.16, respectively) [70]. Those ﬁndings
were consistent with recent large observational studies that were
not included in the meta-analysis [71,72]. Most recently, the
Collaborative Group on Epidemiological Studies of Ovarian Cancer
reported the results of a meta-analysis of 52 epidemiological
studies of HRT use and ovarian cancer risk [73]. The authors
focused on 17 “prospective” studies for which they found a pooled
RR for ovarian cancer of 1.20 (CI: 1.15–1.26) associated with ever-
use of HRT compared to never-use. The association was strongest
among current users of HRT (RR 1.41; 1.32–1.50), with no
difference between women who had used HRT for less than 5
years (1.43) and those with more 5 years of use (1.41). In
accordance with previous studies [71,72,74], substantial risk
differences were seen according to the type of ovarian cancer,
with increased RRs for serous and endometrioid carcinomas and
neutral to decreased RRs for mucinous and clear-cell carcinomas
[73]. The results were similar for oestrogen-only and oestrogen–
progestogen therapy. Based on the results of the meta-analysis, the
authors estimated that 5 years of use of HRT from around age 50
years would result in one additional ovarian cancer case per 1000
users and one additional ovarian cancer death per 1700 users.
However, some have questioned the validity of these estimates and
the existence of a causal relationship between oestrogen–
progestogen therapy and ovarian cancer risk, arguing that the
ﬁndings in the meta-analysis of no duration-risk relationship,
similar results for oestrogen-only and oestrogen-progestogen
therapy, and null associations for “retrospective studies”, are not
readily compatible with a cause-and-effect relationship between
HRT and ovarian cancer risk [75].
2.1.1.4. Other cancers. At least six meta-analyses have reported
that HRT is associated with a decreased risk of colorectal cancer
[76–81]; however, individual studies show considerable variation,
and little risk variation has been observed with different therapy
durations [76,77,79–81]. Only two meta-analyses presented
separate results for oestrogen-only and oestrogen–progestogen
therapies, showing similar and largest risk reductions (20–30%) in
colorectal cancer risk among women currently using oestrogen-
only or oestrogen–progestogen therapy [79,80].
Experimental, clinical, and epidemiological studies have
suggested that HRT may increase the risk of meningioma
[82–86], but decrease the risk of cancers in the upper gastrointes-
tinal tract or lung [80,87–89]. The results for lung cancer may be
inﬂuenced by negative confounding by smoking, and updates of
the WHI Study did not support a protective effect of either
oestrogen-only or oestrogen–progestogen therapy against lung
cancer [90,91].
2.1.2. Hormonal contraceptives
Globally, millions of women of reproductive age use hormonal
contraceptives, and contraceptive use is increasing, notably in
developing countries [92]. Numerous types and preparations of
hormonal contraceptives have been marketed since the late 1950s
[17,93]. Currently, most contraceptives are oral oestrogen–proges-
togen combinations [94]. Based on numerous epidemiological
studies and comprehensive laboratory data, the IARC has
concluded that combined oestrogen–progestogen oral contra-
ceptives increase the risk of cancers of the breast, cervix, and liver,
and reduce the risk of ovarian and endometrial cancer (Table 1)
[2,3,95–97]. Meta-analyses have reported pooled overall RRs from
1.07 to 1.24 for associations between oral contraceptives and breast
cancer, with higher RRs for associations between long-term
contraceptive use and risk of premenopausal breast cancer[98–100]. However, breast cancer risk associated with oral
contraceptives has been consistently reported to approach unity
at 5–10 years after discontinuation [96]: i.e. oral contraceptives
have only limited inﬂuence on the incidence of post-menopausal
breast cancer. For cervical cancer, a comprehensive meta-analysis
of 24 epidemiological studies reported pooled RRs of 0.96,1.20, and
1.56 for invasive cervical cancer associated with oral contraceptive
use for, respectively, <5 years, 5–9 years, and 10 years [101]. After
discontinuation of oral contraceptives, the RRs declined from 1.65
among current users to 1.05 among women who discontinued use
for 10–14 years. Finally, the IARC has also concluded that long-term
use of combined oral contraceptives induces hepatocellular
carcinoma in populations with low prevalence of hepatitis B
infection and chronic liver disease [3]. A meta-analysis of 12 case–
control studies reported an RR of 1.57 (CI: 0.96–2.45) for
hepatocellular carcinoma associated with ever use of oral contra-
ceptives. Individual studies (n = 6) found that long duration of oral
contraceptive use was associated with up to a 20-fold increased
risk of hepatocellular carcinoma, indicating a strong duration–
response relationship, although the statistical precision was
limited in the individual studies [102].
Notwithstanding the adverse effects of oestrogen–progestogen
contraceptives [3,103], the net public health effect of these agents
is beneﬁcial, because they can prevent ovarian and endometrial
cancer, unwanted pregnancies and induced abortions [96]. A
recent comprehensive meta-analysis of 55 studies reported a
pooled RR for ovarian cancer of 0.73 (CI: 0.66–0.81) associated with
ever use of oral contraceptives, and over 50% risk reduction with
10 years use [104]. Epidemiological studies have consistently
shown that women who have ever used oestrogen–progestogen
oral contraceptives have an about 50% reduced risk of endometrial
cancer compared to women who have never used contraceptives
[3,96,105]. Several studies have also suggested that combined
oestrogen–progestogen contraceptives may reduce the risk of
colorectal cancer; however, this evidence is not conclusive [3].
A complete literature review of the inﬂuence of oral contra-
ceptives on cancer risk is outside the scope of the present paper;
however, comprehensive reviews are available in previous IARC
Monographs [2,3] and several meta-analyses [88,96,98–102,
104–120].
2.1.3. Tamoxifen
The anti-oestrogen, tamoxifen, possesses both carcinogenic and
cancer preventive properties [3]. Tamoxifen is indicated as an
adjuvant therapy for postmenopausal, oestrogen-receptor-positive
breast cancer and ductal carcinoma in situ [7,17]. Furthermore,
tamoxifen has been approved as a breast cancer preventive agent
among women at high risk of developing breast cancer (see section
2.2.1) [121,122]. Observational studies and randomised trials have
consistently shown that use of tamoxifen is associated with
approximately a two-fold increased risk of endometrial cancer,
whether given as adjuvant therapy or as a preventive therapy
[3,7,121,122].
2.1.4. Anti-neoplastic therapies
Anti-neoplastic drugs may induce secondary cancer after curing
a primary cancer in children, adolescents [123], and adults [124].
However, the high rate of increased survival or related beneﬁcial
outcome with anti-neoplastic drugs outweighs the risk of
developing secondary cancers; thus, these drugs are endorsed in
clinical practice [125]. Eleven of these agents or combination
therapies have been classiﬁed as carcinogenic to humans by the
IARC (Table 2) [3,14,126]. Of these, the majority are alkylating
agents that exhibit genotoxicity, primarily through alkylation of
purine bases in DNA [127,128]. Typically, these agents induce acute
myeloid leukaemia, which often involves the clonal loss of either
Table 3
Drugs classiﬁed as probably or possibly carcinogenic to humans (Group 2A or 2B,
respectively) assessed by the IARC Monographs Programme.a
Drug Group Monograph volumes Year
Anabolic steroids 2A 10, Suppl. 7b 1987
Azacitidine 2A 50 1990
Aziridine 2B 9, Suppl. 7b, 71 1999
Bleomycin 2B 26, Suppl. 7b 1987
Chloral 2A 63, 106 2015
Chloral hydrate 2A 84, 106 2015
Chloramphenicol 2A 50 1990
Cisplatin 2A Suppl. 7b 1987
Dacarbazine 2B 26, Suppl. 7b 1987
Daunomycin 2B 10, Suppl. 7b 1987
Digoxin 2B 108 2015
Griseofulvin 2B 79 2001
Hydrochlorothiazide 2B 50, 108 2015
Medroxyprogesterone acetate 2B 21, Suppl. 7b 1987
Merphalan 2B 9, Suppl. 7a 1987
Methylthiouracil 2B 79 2001
Metronidazole 2B 13, Suppl. 7b 1987
Mitomycin C 2B 10, Suppl. 7b 1987
Mitoxantrone 2B 76 2000
Oxazepam 2B 66 1996
Pentosanpolysulphate sodium 2B 108 2015
Phenazopyridine hydrochloride 2B 24, Suppl. 7b 1987
Phenobarbital 2B 79 2001
Phenoxybenzamine hydrochloride 2B 24, Suppl. 7b 1987
Phenytoin 2B 66 1996
Pioglitazone 2A 108 2015
Primidone 2B 108 2015
Procarbazine hydrochloride 2A 26, Suppl. 7b 1987
Progestins 2B Suppl. 7a 1987
Progestogen-only contraceptives 2B 72 1999
Propylthiouracil 2B 79 2001
Streptozotocin 2B 17, Suppl. 7b 1987
Sulfasalazine 2B 108 2015
Teniposide 2A 76 2000
Thiouracil 2B 79 2001
Triamterene 2B 108 2015
Zalcitabine 2B 76 2000
Zidovudine 2B 76 2000
a http://monographs.iarc.fr/ENG/Classiﬁcation/index.php.
b IARC monographs Supplement No 7. Overall evaluations of carcinogenicity: an
updating of IARC monographs Volumes 1–42.
S112 S. Friis et al. / Cancer Epidemiology 39S (2015) S107–S119chromosome 5 or 7, although gene translocations also occur
(Table 2) [127–129]. In addition to leukaemia risk, alkylating
chemotherapy has been related to development of solid tumours,
notably cancers of the lung or urinary bladder (Table 2)
[125,129,130]. Several traditional anti-neoplastic drugs have been
supplemented or superseded by newer drugs [93,125], and
research continues to seek ways to reduce dosage or develop
safer, more effective replacement products [125,131].
2.1.5. Immunosuppressive agents
Immunosuppressive agents (Table 2) are typically used to treat
serious chronic conditions such as suppression of host-versus-
graft reactions and rejections of transplants, haematological
diseases, rheumatological diseases, and inﬂammatory bowel
disease [132,133]. Their carcinogenic mechanisms are related to
immunosuppression rather than genotoxicity [3,134,135]. Evi-
dence that immunosuppressant agents are carcinogenic derives
primarily from studies on organ transplantation (Table 1)
[136–138]. Speciﬁcally, there is sufﬁcient evidence that immuno-
suppressants induce non-melanoma skin cancer and non-Hodg-
kin’s lymphoma. Generally, the beneﬁts of these drugs outweigh
their carcinogenicity [134].
2.1.6. Other carcinogenic pharmaceuticals
Phenacetin and phenacetin-containing mixtures induce can-
cers of the renal pelvis and ureter (Table 2) [3]. Although
phenacetin was withdrawn from the market in most countries
around 1980 [3], a lasting impact of these agents cannot yet be
excluded due to the long latency for development of some types of
cancer, and relevant cancers may be diagnosed in future.
Aristolochia plants or seeds are typically used in Chinese herbal
preparations, but have also been found in slimming products used
in a Belgian weight loss clinic, as well as in ﬂour used in bread and
cereals in the Balkans [3,139,140]. Aristolochic acid was identiﬁed
as the carcinogenic agent shortly after the ﬁrst IARC classiﬁcation
of herbal remedies containing plant species of the genus
Aristolochia; on the basis of aristolochic-acid-speciﬁc DNA
mutations in patients with nephropathia or urothelial tumours
who had ingested material from these plants species (Table 2)
[3,140–142]. Although preparations containing Aristolochia seeds
have been banned in Europe for over a decade, Aristolochia seeds
are still detected occasionally in herb shipments to Europe [143].
Methoxsalen, a psoralen found in various plants, is a photosensi-
tizer, used in conjunction with ultraviolet radiation phototherapy
for various conditions [17,144]. Methoxsalen has been suspected to
cause various types of skin cancer, but the association is only
convincing for the combined application of methoxsalen with
ultraviolet A radiation and squamous-cell carcinoma [145].
Photosensitivity is also induced by other frequently used drugs
such as antihypertensives, hydrochlorothiazide (Table 3) and
nifedipine, which are also suspected to increase the risk of lip and
skin cancers [146].
Many of the drugs evaluated by the IARC have been categorised
as probably (Group 2A) or possibly (Group 2B) carcinogenic to
humans, because epidemiological evidence has not been deﬁnitive,
or because carcinogenicity has been demonstrated only in
experimental animals (Table 3). A discussion of these drugs is
outside the scope of the present paper, other than to emphasise the
importance of continued monitoring of carcinogenicity of phar-
maceutical drugs.
2.2. Cancer preventive drugs
Cancer chemoprevention is deﬁned as a pharmacological
intervention, with drugs or nutrient components, which aims to
prevent or inhibit the development of neoplasms [147]. Currently,only a few drugs have been approved for cancer chemoprevention:
i.e. tamoxifen and raloxifene (anti-oestrogens) in prevention of
breast cancer in pre- and post-menopausal women at high risk of
developing breast cancer, and sulindac and celecoxib (non-aspirin
non-steroidal anti-inﬂammatory drugs; NSAIDs) in prevention of
colorectal cancer in patients with hereditary colorectal cancer
syndromes [148,149]. However, several drug categories are
considered deﬁnitely or potentially effective in primary chemo-
prevention, including hormone antagonists, aspirin, statins,
metformin, and 5a-reductase inhibitors.
2.2.1. Hormone antagonists
Several selective oestrogen-receptor modulators (SERMs) and
aromatase inhibitors have been approved for endocrine therapy in
women with hormone-receptor-positive breast cancer [150,151].
However, to date, only the two SERMs tamoxifen and raloxifene
have been approved for preventive therapy in women at high risk
of developing breast cancer [151,152]. A recent meta-analysis of
nine breast cancer prevention trials reported an overall 38%
reduction (RR 0.62; CI: 0.56–0.69) in breast cancer risk associated
with the use of SERMs with a median follow-up of 5.4 years [152];
this effect was due solely to a decreased risk of oestrogen-receptor-
positive breast cancer (RR 0.49; CI: 0.42–0.57). Recent studies have
indicated that aromatase inhibitors, including exemestane and
anastrozol, may have superior efﬁcacy and safety compared to
tamoxifen [153,154], but direct comparisons are lacking.
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A large collection of observational epidemiological studies
[155–158], long-term follow-up for cancer of randomised primary
prevention [159] or cardiovascular [160,161] trials, randomised
trials on colon adenoma recurrence [162–166], and randomised
trials in patients with hereditary colorectal cancer syndromes
[167,168] have established that use of aspirin or other NSAIDs
reduce the risk of colorectal neoplasia and cancer. There is also
substantial evidence to suggest that use of aspirin or non-aspirin
NSAIDs may protect against upper gastrointestinal cancers,
including oesophageal and gastric cancer [158,169–172]. Meta-
analyses of epidemiological studies have also indicated that NSAID
use may protect against breast [158,173–175], lung [158,176,177],
endometrial [178], ovarian [179,180] and prostate [158,181,182]
cancers, but the reported inverse associations of NSAID use with
these cancers are weaker than those demonstrated for gastroen-
terological cancers. The anti-neoplastic mechanisms of NSAIDs are
not entirely clear, although the effect of non-aspirin NSAIDs
appears to be clearly related to inhibition of cyclooxygenase
enzymes [183–185]. The established association between non-
aspirin NSAID use and cardiovascular events has impeded their
potential in cancer prevention [186,187]; thus, evaluations of
NSAID use in cancer prevention have focused on aspirin. Recently,
Cuzick et al. published a comprehensive review of the role of
aspirin in cancer prevention, based on data from systematic
reviews and individual clinical or epidemiological studies of the
beneﬁcial effects (cancer, cardiovascular disease) or adverse events
(gastrointestinal toxicity, haemorrhagic stroke) of aspirin [158].
The authors concluded that aspirin use for a minimum of 5 years
at daily doses between 75 mg and 325 mg appears to have a
favourable beneﬁt–risk proﬁle, notably among individuals be-
tween the ages of 50 and 65 years, and that longer use is likely to
yield a greater beneﬁt. The optimum regimen, however, remains to
be determined [158]. In a pooled analysis of four randomised
cardiovascular trials of aspirin, Rothwell et al. reported that daily
doses of 75–300 mg during median intervention periods of 2.6–6.9
years reduced the 20-year risk of colon cancer by 24% and cancer-
associated mortality by 35%, with 75 mg being as effective as
higher doses [160]. Irrespective of study design, most studies
indicate that a minimum of 5 years of consistent aspirin use is
necessary to achieve a protective effect against colorectal cancer
[156–158].
Several important questions remain unresolved regarding the
association between aspirin use and cancer risk, including the
optimum dose, duration of treatment, timing, and identiﬁcation of
individuals eligible for treatment [158,188]. Future studies and
ongoing randomised trials are necessary to obtain conclusive data
on these issues. Aspirin cannot be recommended for cancer
prevention in the general healthy population because of the risk of
serious adverse events: notably, upper gastrointestinal bleeding
[189], although Cuzick et al. have recently argued that low-dose
aspirin may be considered for prophylactic use against cancer in
segments of the general population [158].
2.2.3. Statins
Increasing experimental evidence has suggested that statins
may have anti-neoplastic effects [190–193]. However, several
randomised trials with cancer as a secondary end-point have
reported that 5–10 years of statin treatment did not reduce the risk
of cancer, overall or at speciﬁc sites [191,194]. Likewise, observa-
tional epidemiological studies with longer follow-up have
generally produced null results, except for slight inverse associ-
ations between statin use and risk of gastrointestinal cancer,
hepatocellular carcinoma, and aggressive prostate cancer
[191,192,194–205]. Statins have also been evaluated as an adjuvant
to standard cancer therapy; however, to date this has yieldedmainly null results [190,191,193]. Additional research should clarify
whether statins have a future role in cancer prevention or therapy.
2.2.4. Metformin
Observational epidemiological studies and meta-analyses have
reported that metformin, a widely used oral antidiabetic drug, may
reduce the risk of several cancer types [206–216]. However, due to
the complex nature of diabetes and the broad array of available
therapies, it is difﬁcult, in observational settings, to discern
whether the inverse association between metformin and cancer
risk is due to an anti-neoplastic effect of metformin or might result
from uncontrolled confounding, when metformin is compared to
other antidiabetics [208,216–218]. Several trials have recently been
launched that aim to assess the potential of metformin for
preventing cancer or cancer recurrence [208,215].
2.2.5. Five-alpha reductase inhibitors
Two large randomised trials have demonstrated that the two
5-alpha reductase inhibitors, ﬁnasteride and dutasteride, used for
treating benign prostatic hyperplasia, reduced the overall risk of
prostate cancer by 25% [219–221]. However, both studies also
found an increased occurrence of aggressive prostate cancer
among patients in the ﬁnasteride arm. It remains unclear whether
the observed increased risk of aggressive prostate cancer is due to
detection bias or a true biological association [219–221]. A recent
18-year update of the ﬁnasteride study reported results for risks of
overall and aggressive prostate cancer compatible with those
during the intervention [222]. Mortality was similar in the
intervention and placebo arms, even when men were stratiﬁed
into low- or high-grade prostate cancer at diagnosis, further
complicating the interpretation of the effect of 5-alpha reductase
inhibitors against prostate cancer. These results and uncertainties
have hindered the use of 5-alpha reductase inhibitors as cancer
preventive agents [221,223,224].
2.3. Carcinogenicity of medical radiation
DNA damage, which through DNA misrepair can lead to the
development of cancer, is the most commonly recognised
mechanism of radiation carcinogenesis. Ionising radiation has
been classiﬁed by the IARC as an established (Group 1) carcinogen
[225]. Key evidence for the carcinogenicity of ionising radiation has
been reviewed by IARC, the United Nations Scientiﬁc Committee on
the Effects of Atomic Radiation [226] and the International
Commission on Radiological Protection [12,227].
2.3.1. Therapeutic medical radiation
The medical applications of ionising radiation include diagnos-
tic examinations and therapy. Radiation treatment for benign
diseases was relatively common until the 1960s. While these
treatments were generally effective for benign diseases – such as
ankylosing spondylitis, post-partum mastitis, peptic ulcer, skin
haemangioma, tinea capitis, enlarged thymus gland, enlarged
tonsils and acne – some treatments also resulted in enhanced
cancer risks [228]. As new treatments have become available and
more has been learned about radiation risks, the use of
radiotherapy for benign disease has declined, whereas the use
of radiotherapy in cancer patients has increased slowly over recent
decades [229]. Cancer radiotherapy delivers high radiation doses
to target organs or tissues of the order of tens of Grays (Gy) [229].
Numerous studies have revealed an increased incidence of second
primary cancers after radiotherapy. These investigations include
both large, comprehensive cohort studies and case–control studies
[225]. In elderly radiotherapy patients, the excess occurrence of
cancer is estimated to be 1.5% at 10 years after treatment and may
appear both at sites adjacent to the radiated area and at sites
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malignancies who underwent radiotherapy experience higher
risks of brain tumours and breast cancer [226]. However, the
precise localisations and risks of second cancers following
radiation therapy is difﬁcult to ascertain because radiotherapy is
often combined with chemotherapy and the separate impact of
these therapeutic measures is difﬁcult to disentangle. Moreover,
the cancer risk pattern among patients with previous cancers may
differ from that of the general population for other reasons.
The impact of radiation-induced tumours in radiotherapy
patients becomes increasingly important as better survival leads
to more long-term survivors, and clinicians are becoming more
aware of the potential long-term consequences of high-dose
radiotherapy. As a result, radiotherapy doses have been reduced for
Hodgkin’s disease, testicular cancer, and breast cancer [231]. New
technologies are being increasingly introduced, such as intensity-
modulated radiation therapy (which allows changes in the
intensity of the radiation beams during treatment sessions) and
proton beam therapy with pencil scanning beam; these are highly
targeted types of radiotherapy that can treat hard-to-reach cancers
with a potentially lower risk of damaging the surrounding tissue
and inducing second cancers [229].
2.3.2. Diagnostic medical radiation
Since 1956, epidemiological studies have linked diagnostic
X-rays with increased cancer risk. Important ﬁndings include a
modest increase in childhood leukaemia among the offspring of
mothers who underwent pelvic X-rays during pregnancy
[232,233], and an excess of breast cancer among women
monitored with ﬂuoroscopy for tuberculosis [231,234,235], or
undergoing repeated X-rays for scoliosis [236].
Distinct beneﬁts derive from the use of diagnostic x-rays and
the potential cancer risk to an individual is small; it has been
estimated that diagnostic X-ray use in the UK causes 0.6% of the
cumulative risk of cancer to age 75 years [237]. Nevertheless, the
large number of people exposed means that even small individual
risks translate into a considerable number of cancer cases on a
population level. This delicate balance between beneﬁt and risk
demands the judicious use of diagnostic radiation.
Diagnostic use of radiation is a rapidly changing ﬁeld. During
the past 30 years, newer imaging techniques – e.g. multi-slice CT,
nuclear imaging, and PET-CT – have increased dramatically [229].
These procedures have increased the clinical beneﬁt but have also
resulted in higher radiation exposures to patients compared with
exposures attributable to conventional radiography, for which
average doses per examination have decreased with improved
technology. Dramatic increase in the use of CT have raised concerns
especially for paediatric patients, because children are more
sensitive to harmful effects of ionising radiation and because CT
protocols used for children, particularly in the past, were not
always adjusted for smaller body size and therefore resulted in
inappropriately high exposures. Recent studies in the UK and
Australia have shown increased risks of childhood cancer, notably
leukaemia and brain cancer, following CT examinations [238,239].
The UK study estimated that per 10,000 head CT scans at ages
below 10 years, one extra case of leukaemia and one extra case of
brain tumour will occur within 10 years after the CT scan [239]. The
potential increase in future cancer occurrence attributable to the
rapid expansion in CT use have increased awareness in the medical
community and efforts have been made to ensure that diagnostic
procedures involving ionising radiation are performed only if
absolutely necessary for a patient’s care (justiﬁed) and to provide
images adequate for diagnosis while keeping the radiation dose
levels as low as reasonably achievable (optimisation). These
principles are notably enforced for paediatric patients.3. Scientiﬁc justiﬁcation of the recommendation
In summary, current evidence shows that HRT is associated
with an increased risk of cancers of the breast, endometrium, and
ovary [3]. The risk pattern depends on the type of therapy
(oestrogen-only or combined oestrogen–progestogen), initiation
according to time of menopause, and whether the woman has
undergone hysterectomy. The European Code against Cancer
recommends limiting or avoiding, when possible, the use of
HRT, i.e. mainly menopausal hormone therapy, due to the
increased cancer risk. Women with severe menopausal symptoms
may discuss with their physician whether to use HRT; however, it
should not be used for purposes of disease prevention. The
therapeutic approach should be discussed thoroughly with the
physician before treatment is started. The individual clinician is
obligated to inform women on the risks and beneﬁts of HRT to
ensure that patients make informed, individualised decisions. In
general, menopausal hormone treatment should employ the
lowest dose for the shortest period possible. More research is
needed on HRT to clarify the implications related to cancer risk.
Ionising radiation is an established carcinogen, and medical
applications of radiation for diagnosis and treatment are major
sources of radiation exposure for the European population.
Application of medical radiation can provide major health beneﬁts,
but due to the potential increase in cancer risk, prudent practises
ensuring justiﬁcation in terms of beneﬁts and harms are required,
with procedures and techniques providing the needed diagnostic
information or therapeutic gain with the least possible radiation
exposure.
4. Conclusions
Principles of the 4th revision of the European Code against
Cancer were that the recommendations are (1) based on sufﬁcient
scientiﬁc evidence of carcinogenicity, (2) suitable for a broad target
group, (3) something individuals can do to reduce their cancer risk,
and (4) that the recommendations can be clearly communicated to
the general population [1]. All four principles were judged to be
fulﬁlled for HRT, although HRT has a certain therapeutic potential
after thorough beneﬁt–risk evaluation by physicians. For other
medical exposures, the established carcinogenic effects were not
conceived to be clearly communicable to the general population,
exempliﬁed by diagnostic X-ray which poses undue risk if used
unnecessarily, but also cause an important health risk if a
necessary examination is avoided because of fear of radiation.
Other drugs with established carcinogenic effects in humans
include anti-neoplastic agents used in cancer therapy, immuno-
suppressants, oestrogen–progestogen contraceptives, and tamoxi-
fen. Prescription of carcinogenic drugs for cancer-free individuals
should be based on careful beneﬁt–risk considerations and the
available evidence [3,5]. Targeted treatments with tamoxifen,
aromatase inhibitors and immunosuppressants are typically
endorsed from a clinical perspective. In contrast, hormonal
contraceptives cannot be recommended alone from a cancer
perspective, since these agents possesses both cancer preventive
and carcinogenic effects. Because oral contraceptives are pre-
scribed for healthy individuals, any decision to use these drugs
should be based on a thorough evaluation of the risk–beneﬁt
proﬁle of each individual woman. Irrespective of drug type, long-
term monitoring of potential carcinogenic risk is imperative. No
straightforward recommendation can be given to the general
population.
Although a large number of chemopreventive agents have been
investigated, to date none has been found to be clinically useful,
except within selected, high-risk groups. Therefore, further
research is required to ﬁnd chemopreventive agents that are
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mended for the healthy population, but these agents provide a
potential therapeutic option for individuals at high risk of
developing cancer. Any chemopreventive approach should be
started only after consulting a physician who can supervise the
treatment. Self-medication with aspirin or other potential
chemopreventive drugs is strongly discouraged, due to the
possibility of serious, potentially lethal, adverse events.
Radiation therapy is established to cause an increased risk of
second primary cancer; however, the absolute excess is small, and
the beneﬁts of radiation therapy virtually always outweigh the
risks. Similarly, high-dose diagnostic procedures, such as CT, are
associated with a small cancer risk, but the immediate beneﬁts of
CT generally outweigh the long-term risks, if used diligently.
Clinicians face the task of making decisions about the beneﬁt to the
patient in relation to the small excess cancer risk associated with
radiation exposure; however, existing guidelines and recommen-
dations are helpful in this decision-making. Therefore, although
the diagnostic procedures involving ionising radiation increase the
risk of cancer development, the vast majority of examinations are
medically justiﬁed and provide overall beneﬁt to the patients. No
recommendation can be given to the general population, as
healthcare professionals represent the target group for continu-
ously updated information of carcinogenic effects of radiation, and
avoidance of unnecessary use.
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